No excess mortality observed in long-term care residents who survived acute SARS-CoV-2 infection

The coronavirus disease 2019 (COVID-19), which is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over six million deaths to date around the world.

Many of these fatalities occurred in long-term care (LTC) facilities of high-income countries, with a mortality rate of 10-40% recorded among these LTC facility residents. For example, Swedish LTC residents reported a thirty-day mortality rate of 40% among SARS-CoV-2 infected individuals, which was only 6% in matched controls without the infection.

However, the long-term effects of SARS-CoV-2 infection on mortality of LTC residents who recover from COVID-19 remain uncertain. Additionally, the life expectancy in the population post-acute phase (after thirty days) of the disease remains controversial.

Study: Time-Varying Death Risk After SARS-CoV-2-Infection in Swedish Long-Term Care Facilities. Image Credit: triocean / Shutterstock.com

Study: Time-Varying Death Risk After SARS-CoV-2-Infection in Swedish Long-Term Care Facilities. Image Credit: triocean / Shutterstock.com

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

About the study

In a recent study published on the medRxiv* preprint server, researchers evaluate the mortality rate in Swedish LTC facilities for eight months after patients had recovered from acute SARS-CoV-2 infection.

This retrospective cohort study included a total of 3.721 Swedish LTC residents over the age of 65 years who were infected with SARS-CoV-2, as well as 3,731 control who were matched (1:1) based on their age, body mass index (BMI), gender, comorbidities, health status, and prescription medication usage.

The primary outcome that the researchers were interested in assessing was all-cause mortality among infected residents as compared to controls. To calculate the absolute risk of death, the researchers use Kaplan-Meier plots, whereas hazard ratio (HR) for death was plotted over time using flexible parametric models.

Study findings

The median age of the residents was 87 years, with 65% of the study cohort consisting of females. Notably, comorbidities were frequently reported among LTC residents. SARS-CoV-2 infections exhibited a sharp and early increased predisposition for death, at 40% in the infected group and 6% in the control group.

At 210 days after the onset of infection, the survival of controls was 74.3%. In the sensitivity analysis, the survival estimate was 82.9%, with a median survival of 577 days. Among controls matched to 1,487 SARS-CoV-2-infected residents who passed away in the first month, the median survival was 577 days.

Hazard ratio for death in residents with SARS-CoV-2, as compared with controls in (A) the main analysis and (B) the sensitivity analysis.

Hazard ratio for death in residents with SARS-CoV-2, as compared with controls in (A) the main analysis and (B) the sensitivity analysis.

HR peaked five days post-infection and remained high in the first 30 days until it ultimately declined to 1.0 in the second month and remained at this level. In the sensitivity analysis, the HR peak was 21.5 and decreased sharply until it ultimately declined to below 1.0 after the second month and remained at this level for the remainder of the study period.

A total of 1,487 deaths occurred among the infected residents as compared to 211 uninfected controls in the first month. Over the following month, 93 and 144 were recorded in the two cohorts, respectively. In the third and fourth months of follow-up, 33 and 121 deaths, and 38 and 126 deaths, respectively, were reported.

In the subsequent months, a similar pattern was observed. Meanwhile, 133 deaths occurred between 61-210 days after infection among SARS-CoV-2 infected residents as compared to 420 deaths that were recorded in the controls, with an HR of 0.41. The sensitivity analysis revealed 131 deaths among infected individuals and 278 deaths in the uninfected control group with an HR of 0.76.

Conclusions

No excess mortality was detected among LTC facility residents after the acute phase of SARS-CoV-2 infection. Nevertheless, the life expectancy based on age and sex was much lower in uninfected LTC residents as compared to the general population.

The study findings suggest that life expectancy is not reduced in LTC residents who survive the acute phase of SARS-CoV-2 infection. Of note, the death rate was reduced in longer follow-ups despite concerns regarding residual debilitation after infection.

The first wave of COVID -19 in Swedish LTC facilities led to an average loss of life expectancy of fewer than 1.6 years, which is much lower when compared to that in the general population.

Determining the burden of COVID-19 by calculating the years of life lost based on age and gender-dependent life expectancy, without considering general health and LTC residence, can yield inflated estimates. Thus, sufficient information on comorbidities should be considered when estimating years of life lost to calculate the true morbidity of COVID-19.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 18 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Nidhi Saha

Written by

Nidhi Saha

I am a medical content writer and editor. My interests lie in public health awareness and medical communication. I have worked as a clinical dentist and as a consultant research writer in an Indian medical publishing house. It is my constant endeavor is to update knowledge on newer treatment modalities relating to various medical fields. I have also aided in proofreading and publication of manuscripts in accredited medical journals. I like to sketch, read and listen to music in my leisure time.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Saha, Nidhi. (2023, May 18). No excess mortality observed in long-term care residents who survived acute SARS-CoV-2 infection. News-Medical. Retrieved on December 23, 2024 from https://www.news-medical.net/news/20220316/No-excess-mortality-observed-in-long-term-care-residents-who-survived-acute-SARS-CoV-2-infection.aspx.

  • MLA

    Saha, Nidhi. "No excess mortality observed in long-term care residents who survived acute SARS-CoV-2 infection". News-Medical. 23 December 2024. <https://www.news-medical.net/news/20220316/No-excess-mortality-observed-in-long-term-care-residents-who-survived-acute-SARS-CoV-2-infection.aspx>.

  • Chicago

    Saha, Nidhi. "No excess mortality observed in long-term care residents who survived acute SARS-CoV-2 infection". News-Medical. https://www.news-medical.net/news/20220316/No-excess-mortality-observed-in-long-term-care-residents-who-survived-acute-SARS-CoV-2-infection.aspx. (accessed December 23, 2024).

  • Harvard

    Saha, Nidhi. 2023. No excess mortality observed in long-term care residents who survived acute SARS-CoV-2 infection. News-Medical, viewed 23 December 2024, https://www.news-medical.net/news/20220316/No-excess-mortality-observed-in-long-term-care-residents-who-survived-acute-SARS-CoV-2-infection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How viral persistence and immune dysfunction drive long COVID